VERTEX PHARMACEUTICALS INC / MA

VRTX · Healthcare · $122.8B mkt cap · FY2025 filings · Wide moat

On the watchlist

Wide moat

The four filters

Pricing power100

Median gross margin 87.4% over 10y, very stable.

Returns on capital96

Median ROIC 35.6%, above the 9% hurdle in 89% of years.

Balance-sheet safety73

Net debt/EBITDA n/ax, interest coverage 314x.

Capital discipline39

Owner earnings trend unclear, share count growing (dilution).

Margin of safety

Above valueOn sale

105% above value

Owner earnings (normalized): $3.3B
Est. intrinsic value / share: $235.43
Recent price: $483.34
Discount to value: 105% above value

Conservative model: 9% discount rate, 4% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

Moat Score history

Score history begins 2026-07-17. Check back as the record builds.

Scores are logged append-only and never overwritten — this record can't be backfilled, which is exactly why it's worth keeping.

Embed this score on your site

One iframe, no script. The badge shows VRTX’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/VRTX"
  width="340" height="150" style="border:0"
  title="VRTX Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell VRTX. See the disclaimer.